These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21305353)

  • 1. Non-invasive measurements of atherosclerosis in adult cystinosis patients.
    Besouw MT; Holewijn S; Levtchenko EN; Janssen MC
    J Inherit Metab Dis; 2011 Jun; 34(3):811-8. PubMed ID: 21305353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fertility status in male cystinosis patients treated with cysteamine.
    Besouw MT; Kremer JA; Janssen MC; Levtchenko EN
    Fertil Steril; 2010 Apr; 93(6):1880-3. PubMed ID: 19217094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
    Nesterova G; Williams C; Bernardini I; Gahl WA
    Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management dilemmas in pediatric nephrology: Cystinosis.
    Besouw MT; Van Dyck M; Cassiman D; Claes KJ; Levtchenko EN
    Pediatr Nephrol; 2015 Aug; 30(8):1349-60. PubMed ID: 25956701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis.
    Levtchenko EN; van Dael CM; de Graaf-Hess AC; Wilmer MJ; van den Heuvel LP; Monnens LA; Blom HJ
    Pediatr Nephrol; 2006 Jan; 21(1):110-3. PubMed ID: 16252107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate.
    Langman CB; Greenbaum LA; Grimm P; Sarwal M; Niaudet P; Deschenes G; Cornelissen EA; Morin D; Cochat P; Elenberg E; Hanna C; Gaillard S; Bagger MJ; Rioux P
    J Pediatr; 2014 Sep; 165(3):528-33.e1. PubMed ID: 24948347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carotid stiffness and atherosclerotic risk: non-invasive quantification with ultrafast ultrasound pulse wave velocity.
    Zhu ZQ; Chen LS; Wang H; Liu FM; Luan Y; Wu LL; Liu N; Wang P; Huang H
    Eur Radiol; 2019 Mar; 29(3):1507-1517. PubMed ID: 30187117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis.
    Veys KRP; Elmonem MA; Van Dyck M; Janssen MC; Cornelissen EAM; Hohenfellner K; Prencipe G; van den Heuvel LP; Levtchenko E
    J Am Soc Nephrol; 2020 May; 31(5):1092-1106. PubMed ID: 32273301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy.
    Sonies BC; Almajid P; Kleta R; Bernardini I; Gahl WA
    Medicine (Baltimore); 2005 May; 84(3):137-146. PubMed ID: 15879904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-up and treatment of adults with cystinosis in the Netherlands.
    Geelen JM; Monnens LA; Levtchenko EN
    Nephrol Dial Transplant; 2002 Oct; 17(10):1766-70. PubMed ID: 12270982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cystinosis: an infrequent cause of distal myopathy].
    Rodríguez-Gómez FJ; López-Domínguez JM; Borrero-Martín JJ; Rodríguez-Gómez E; Chinchón-Lara I; Pujol-De la Llave E
    Rev Neurol; 2005 Feb 1-15; 40(3):156-8. PubMed ID: 15750900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of topical cysteamine in nephropathic cystinosis.
    Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
    Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up.
    Dohil R; Cabrera BL
    Pediatr Nephrol; 2013 Mar; 28(3):507-10. PubMed ID: 23001048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenchymal organ cystine depletion with long-term cysteamine therapy.
    Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
    Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired structural genitourinary abnormalities contributing to deterioration of renal function in older patients with nephropathic cystinosis.
    Strife CF; Strife JL; Wacksman J
    Pediatrics; 1991 Dec; 88(6):1238-41. PubMed ID: 1956743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of cystinosis in children with twice-daily cysteamine.
    Dohil R; Gangoiti JA; Cabrera BL; Fidler M; Schneider JA; Barshop BA
    J Pediatr; 2010 May; 156(5):823-7. PubMed ID: 20138296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early cardiovascular manifestations in children and adolescents with autosomal dominant polycystic kidney disease: a single center study.
    Karava V; Benzouid C; Hogan J; Dossier C; Denjean AP; Deschênes G
    Pediatr Nephrol; 2018 Sep; 33(9):1513-1521. PubMed ID: 29774463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic challenge in a patient with nephropathic juvenile cystinosis: a case report.
    Higashi S; Matsunoshita N; Otani M; Tokuhiro E; Nozu K; Ito S
    BMC Nephrol; 2017 Sep; 18(1):300. PubMed ID: 28950840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.